CANF - Can-Fite BioPharma Ltd.
After hours:
Chart Events
Double Moving Average Crossover
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 2.3300 |
| Open | 2.2700 |
| Bid | 2.2300 x 3100 |
| Ask | 2.4400 x 1800 |
| Day's Range | 2.2400 - 2.3683 |
| 52 Week Range | 1.5200 - 11.2000 |
| Volume | |
| Avg. Volume | 55,537 |
| Market Cap | 9.145M |
| Beta (5Y Monthly) | 0.80 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.9500 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 40.83 |
Fair Value
Related Research
Business WireCan-Fite: Presenting Namodenoson’s New Pancreatic Cancer Indication to Potential Partners at BioEquity Europe 2023
PETACH TIKVA, Israel, May 15, 2023--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer, and liver diseases, today announced its VP of Business Development, Dr. Sari Fishman, will participate in BioEquity Europe which takes place on May 14th – 16th, 2023 in Dublin, Ireland.
ZacksAll You Need to Know About Can-Fite Biopharma Ltd (CANF) Rating Upgrade to Buy
Can-Fite Biopharma Ltd (CANF) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Business WireCan-Fite to Initiate Exploratory Phase 2 Trial with Namodenoson in Pancreatic Cancer Patients
PETACH TIKVA, Israel, May 09, 2023--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced that it will initiate an open-label Phase 2 exploratory trial to assess the efficacy and safety of Namodenoson in the treatment of patients with pancreatic cancer who have received at least one previous systemic therapy.
Business WireInhibition of Pancreatic Cancer by Namodenoson: Molecular Mechanism of Action Discovered by Can-Fite Scientists
PETACH TIKVA, Israel, May 02, 2023--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced that it discovered the mechanism of action (MOA) involved with the significant anti-cancer effect of Namodenoson in pancreatic carcinoma. Namodenoson de-regulates the Wnt signal transduction pathway, a key modulator of pancreatic carcinoma cell growth.
Business WireCan-Fite Announces New Management Structure as Advanced Stage Pipeline Moves Toward Commercialization
PETACH TIKVA, Israel, April 24, 2023--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced executive changes to support the Company’s continued success in advancing its pipeline toward commercialization through two pivotal Phase III trials in psoriasis and liver cancer.
Business WireCan-Fite: EMA Gives Green Light for Piclidenoson Pivotal Phase III Clinical Trial for Psoriasis Treatment
PETACH TIKVA, Israel,, April 10, 2023--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced that it received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) with respect to the submission of a registration plan for a pivotal Phase III clinical trial for the treatment o
Business WireCan-Fite Reports 2022 Financial Results & Provides Clinical Update
PETACH TIKVA, Israel, March 30, 2023--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced financial results for the year ended December 31, 2022.
Business WireCan-Fite to Conduct Meetings at the BIO-Europe Spring Conference with Pharma Companies Interested in Licensing and Distributing Piclidenoson and Namodenoson
PETACH TIKVA, Israel, March 16, 2023--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, announced today that Dr. Sari Fishman, the Company’s Vice President of Business Development, will participate in the BIO-Europe Spring® partnering conference in Basel, Switzerland from March 20 to 22, 2023. Dr. Fishman will conduct one-on-one meetings with a substantial nu
Business WireCan-Fite to Treat Decompensated Liver Cirrhosis Patients with Namodenoson Under Compassionate Use Setting
PETACH TIKVA, Israel, March 13, 2023--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, announced today that patients with decompensated cirrhosis, an advanced form of cirrhosis associated with liver failure for which there are no therapeutic options other than liver transplantation, will be treated with Namodenoson at the Soroka Medical Center in Israel unde
Business WireNovel Approach to Treating Advanced Liver Cancer with Namodenoson Published in Leading Scientific Journal: 12-Month Survival of 44% for Namodenoson vs. 18% for Placebo
PETACH TIKVA, Israel, February 14, 2023--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced that Purinergic Signalling, a peer-reviewed scientific journal focused on molecules which target adenosine receptors, published an article titled "Targeting the A3 adenosine receptor to treat hepatocellular carcinoma: anti-cancer and hepatoprotecti
Business WireCan-Fite: Namodenoson Significantly Inhibits Pancreatic Cancer in Preclinical Studies—A Patent Has Been Filed
PETACH TIKVA, Israel, January 24, 2023--Can-Fite: Namodenoson Significantly Inhibits Pancreatic Cancer in Preclinical Studies—A Patent Has Been Filed
Business WireCan-Fite Announces $7.5 Million Concurrent Registered Direct Offering and Private Placement
PETACH TIKVA, Israel, January 11, 2023--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases ("Can-Fite" or the "Company"), today announced that it has entered into definitive agreements for the purchase and sale of 1,000,000 of the Company’s American Depositary Shares ("ADSs") (or ADS equivalents in lieu thereof), at a purchase price of $5.50 per ADS, in a
Business WireCan-Fite Submits Market Registration Plan to European Medicines Agency for Piclidenoson in the Treatment of Psoriasis; FDA Submission to Follow
PETACH TIKVA, Israel, January 10, 2023--Can-Fite Submits Market Registration Plan to European Medicines Agency for Piclidenoson in the Treatment of Psoriasis; FDA Submission to Follow
Business WireCan-Fite Announces ADS Ratio Change
PETACH TIKVA, Israel, December 30, 2022--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, announced today that the Company will change the ratio of its American Depositary Shares (ADSs) to ordinary shares from one (1) ADS representing thirty (30) ordinary shares to a new ratio of one (1) ADS representing three hundred (300) ordinary shares. The ratio c
ZacksMinerva (NERV) Down; FDA Denies Review Schizophrenia Drug NDA
Minerva (NERV) confirmed that the FDA's refuse-to-file letter on its regulatory filing, seeking approval for roluperidone, to treat symptoms of schizophrenia remains in effect.
BenzingaCan-Fite's Namodenoson Increases Survival For Most Severe Patients With Advanced Liver Cancer
Can-Fite BioPharma Ltd (NASDAQ: CANF) provided an update on its clinical program for Namodenoson for hepatocellular carcinoma (HCC). At two upcoming conferences, Can-Fite will present the latest data comparing the response of liver cancer patients to those with HCC Child-Pugh B (CPB) and share the latest findings on a CPB liver cancer patient who remains cancer-free six years after she began treatment with Namodenoson. Can-Fite's prior Phase 2 study showed that median overall survival in the CPB
Business WireCan-Fite Updates: Namodenoson Increases Survival for the Most Severe Patients with Advanced Liver Cancer
PETACH TIKVA, Israel, December 28, 2022--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today provided an update on its clinical program for Namodenoson in the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer. A pivotal Phase III registration study is open for enrollment of the most advanced liver cancer patients. At
News DirectMultiple Shots On Goal: Can-Fite’s Late-Stage Clinical Pipeline Hits Positive Results
By Ernest Dela Aglanu, Benzinga
Business WireCan-Fite’s Partner Vetbiolix is Heading into a European Multicentric Clinical Trial with Piclidenoson for the Treatment of Pets’ Osteoarthritis
PETACH TIKVA, Israel, December 08, 2022--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced progress achieved in the development of Piclidenoson for` the treatment of osteoarthritis in dogs by the Company’s veterinary commercialization partner Vetbiolix, which is covering all costs associated with veterinary clinical development. The cani
Business WireCan-Fite Reports Third Quarter 2022 Financial Results & Provides Clinical Update
PETACH TIKVA, Israel, November 25, 2022--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced financial results for the quarter ended September 30, 2022.
ZacksCatalyst's (CPRX) Q3 Earnings & Revenues Surpass Estimates
Catalyst's (CPRX) earnings and revenues beat estimates for the third quarter of 2022. The company increases the full-year revenue guidance.
ZacksPacira's (PCRX) Q3 Earnings Miss Estimates, Revenues Beat
Pacira's (PCRX) earnings fall shy of estimates in the third quarter of 2022 while revenues beat the same.
ZacksCorcept's (CORT) Q3 Earnings Beat Estimates, Revenues Miss
Corcept's (CORT) third-quarter 2022 earnings beat estimates while revenues miss the same. The company tightens its revenue guidance for 2022. Shares down in after-hours trading.
Business WireCan-Fite: Positive New Data from it’s Phase III Psoriasis Study will be Presented Today at an Industry Expert Summit in Boston
PETACH TIKVA, Israel, November 02, 2022--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, announced today the Company’s CEO, Dr. Pnina Fishman, will deliver a presentation titled "Piclidenoson for the Treatment of Psoriasis: Clinical Development and Mechanism of Drug Action" at the 6th Annual Dermatology Drug Development Summit for Inflammatory Skin Di
News DirectThis Company Is Racing Toward Providing Comfort And Safety To Millions Of Psoriasis Sufferers
By Mark Gilman, Benzinga